Skip to content

Moderna MRNA Price / earnings

Price / earnings at other companies

Pfizer logo
PfizerPFE
14.7×
ALN
Alnylam PharmaceuticalsALNY
87.4×
Roivant Sciences logo
Roivant SciencesROIV
249.7×+248×
Biogen logo
BiogenBIIB
18.9×+5.4×
Merck & Co. logo
Merck & Co.MRK
33.3×+20.3×
Johnson & Johnson logo
Johnson & JohnsonJNJ
28×+9.7×

Other financials

Income statement

See full
Revenue$389.0M+260%
Gross profit-$566.0M-3,244%
Operating income-$1.4B-32.2%
Net income-$1.3B-38.3%
EPS (diluted)-$3.40-34.9%

Balance sheet

See full
Cash & equivalents$1.9B+17.4%
Total debt$1.3B+71.9%
Total equity$7.4B-26.4%
Total assets$11.5B-9.6%

Cash flow

See full
Operating cash flow-$630.0M+39.3%
CapEx$62.0M-47.0%
Free cash flow-$692.0M+40.0%

Valuation

See full
Market cap$25.38B+83.8%
Enterprise value$24.8B+93.6%
P/S11.4×+7.1×

Profitability

See full
Gross margin22.1%-32.0pp
Operating margin-153.3%+67.8pp
Net margin-143.6%+80.2pp

Returns & leverage

See full
Return on equity-36.6%+11.9pp
Debt / equity0.2×+0.1×
Current ratio2.4×-1.8×

Where this comes from

Calculated from Moderna’s reported figures.

Based on the most recent quarter.

The official record: Moderna’s 10-Q, filed August 1, 2024, on SEC EDGAR. View the filing →

Ask your AI about Moderna's price / earnings.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Moderna's price / earnings?
Moderna (MRNA) reported price / earnings of 38.4× in Q2 2023.
How has Moderna's price / earnings changed year-over-year?
Moderna's price / earnings increased by 849.2% year-over-year, from 4× to 38.4×.
What does price / earnings mean?
How many dollars investors pay for each dollar of the company's annual profit.
How do you interpret price / earnings?
Lower can mean cheaper — or that the market expects earnings to fall. High multiples embed growth expectations. Meaningless when earnings are negative, so it is suppressed there.
How does price / earnings compare across companies?
Compare against the company's own history and sector peers, not across sectors with different growth and risk profiles.